{"gene":"SLFN12","run_date":"2026-04-28T20:42:08","timeline":{"discoveries":[{"year":2021,"finding":"SLFN12 is an RNase enzyme whose activity is required for DNMDP-induced cancer cell death; PDE3A and SLFN12 form a heterotetramer stabilized by DNMDP binding, and interactions between the C-terminal alpha helix of SLFN12 and residues near the PDE3A active site are required for complex formation, which increases SLFN12 RNase activity.","method":"Cryo-EM/X-ray structure determination, in vitro RNase assay, mutagenesis of SLFN12 C-terminal helix and PDE3A interface residues, reconstituted complex formation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal/cryo-EM structure plus in vitro enzymatic assay plus mutagenesis, confirmed in multiple independent studies","pmids":["34272366"],"is_preprint":false},{"year":2021,"finding":"PDE3A-SLFN12 forms a butterfly-shaped heterotetramer complex stabilized by molecular glue compounds (DNMDP, anagrelide, nauclefine) that bind the PDE3A catalytic pocket and create a new interface recruiting the short helix (E552-I558) of SLFN12 through hydrophobic interactions; the complex blocks protein translation leading to apoptosis.","method":"High-resolution cryo-EM structure of PDE3A-SLFN12 complexes isolated from HeLa cells treated with different molecular glues, structure-based analog design validated in cell viability and xenograft assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — high-resolution cryo-EM structure with functional validation, independent of PMID:34272366","pmids":["34707099"],"is_preprint":false},{"year":2022,"finding":"The physiological substrate of SLFN12 RNase is tRNALeu(TAA); SLFN12 selectively cleaves tRNALeu(TAA) at distinct sequences in its variable loop and acceptor stem, and velcrin-induced PDE3A-SLFN12 complex formation promotes this cleavage in vitro and in cells, leading to ribosome pausing at Leu-TTA codons and global inhibition of protein synthesis, thereby initiating apoptosis.","method":"In vitro tRNA cleavage assay with purified SLFN12, mutational analysis of tRNA substrate sequences, ribosome profiling of velcrin-treated cells, measurement of tRNALeu(TAA) levels and global protein synthesis in sensitive cancer cells","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstituted RNase assay with substrate mutagenesis plus cellular ribosome profiling, multiple orthogonal methods","pmids":["36302897"],"is_preprint":false},{"year":2022,"finding":"Molecular glue compounds induce PDE3A-SLFN12 complex formation, which increases SLFN12 protein stability in the cytoplasm and induces dephosphorylation of SLFN12 at serines 368 and 573; this dephosphorylation is required for cell death and promotes SLFN12 rRNA RNase activity.","method":"Mutational analysis of phosphoserine residues, western blot for phosphorylation status, cell viability assays with phosphomimetic/phospho-null mutants, in vitro RNase assay with dephosphorylated vs. phosphorylated SLFN12","journal":"Cell chemical biology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis of specific phosphosites with in vitro RNase activity readout and cell death phenotype","pmids":["35104454"],"is_preprint":false},{"year":2022,"finding":"SLFN12 overexpression in triple-negative breast cancer cells reduces CHK1 and CHK2 phosphorylation after DNA damage (camptothecin treatment), and CHK1/CHK2 inhibition diminishes the sensitization to carboplatin conferred by SLFN12 overexpression, placing SLFN12 upstream of checkpoint kinase signaling in DNA damage response.","method":"Lentiviral SLFN12 overexpression, western blot for pCHK1/pCHK2, pharmacological CHK1/CHK2 inhibition (AZD7762), crystal violet viability assay in multiple TNBC cell lines","journal":"Cancer genomics & proteomics","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic epistasis with pharmacological inhibitor rescue, replicated in multiple cell lines but no direct biochemical mechanism established","pmids":["35430566"],"is_preprint":false},{"year":2024,"finding":"SLFN12 RNase-mediated cell death in GISTs activates the GCN2 (general control non-derepressible 2) kinase and its downstream integrated stress response as an effector pathway mediating anticancer activity.","method":"OPB-171775 (PDE3A-SLFN12 complex inducer) treatment in patient-derived xenograft GIST models, mechanistic pathway analysis identifying GCN2 activation as downstream effector","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 — pathway placement in PDX models, consistent with known tRNA cleavage mechanism activating GCN2, but limited biochemical detail reported","pmids":["38864850"],"is_preprint":false}],"current_model":"SLFN12 is a cytoplasmic RNase that, when recruited into a heterotetramer with PDE3A by molecular glue compounds (velcrins), undergoes dephosphorylation at S368/S573 and increased enzymatic activity, selectively cleaving tRNALeu(TAA) to cause ribosome pausing at Leu-TTA codons, global translation inhibition, and apoptotic cell death; complex formation requires the C-terminal alpha helix of SLFN12 engaging a compound-modified hydrophobic interface near the PDE3A catalytic site."},"narrative":{"teleology":[{"year":2021,"claim":"Establishing that SLFN12 possesses RNase activity and forms a structurally defined heterotetramer with PDE3A resolved a key question about how velcrin compounds kill cancer cells — not through PDE3A catalytic inhibition but through induced proximity that activates SLFN12 enzymatic function.","evidence":"Cryo-EM and X-ray crystallography of PDE3A–SLFN12 complexes, in vitro RNase assays, and mutagenesis of the SLFN12 C-terminal helix and PDE3A interface residues","pmids":["34272366","34707099"],"confidence":"High","gaps":["Physiological RNA substrate of SLFN12 RNase was not identified","Mechanism by which RNase activity leads to cell death was unclear","Whether endogenous (non-drug-induced) signals regulate complex formation was unknown"]},{"year":2022,"claim":"Identification of tRNALeu(TAA) as the selective physiological substrate of SLFN12 explained how its RNase activity causes translation arrest and apoptosis — cleavage depletes a specific tRNA, stalling ribosomes at cognate codons genome-wide.","evidence":"In vitro tRNA cleavage assays with purified SLFN12, substrate mutagenesis defining cleavage sites, and ribosome profiling showing pausing at Leu-TTA codons in velcrin-treated cells","pmids":["36302897"],"confidence":"High","gaps":["Whether SLFN12 cleaves additional tRNA species under different conditions was not resolved","Structural basis for tRNALeu(TAA) selectivity over other tRNAs was not determined","How ribosome pausing at specific codons triggers apoptotic commitment remained undefined"]},{"year":2022,"claim":"Discovery that velcrin-induced complex formation triggers dephosphorylation of SLFN12 at S368 and S573, and that this dephosphorylation is required for RNase activation and cell death, revealed a post-translational regulatory switch controlling SLFN12 enzymatic output.","evidence":"Phosphomimetic and phospho-null mutagenesis, western blot for phosphorylation status, in vitro RNase assay comparing phosphorylated and dephosphorylated SLFN12, and cell viability assays","pmids":["35104454"],"confidence":"High","gaps":["Identity of the phosphatase(s) responsible for S368/S573 dephosphorylation was not established","The kinase(s) maintaining basal SLFN12 phosphorylation were not identified","Whether dephosphorylation alters SLFN12 substrate specificity or only catalytic rate was not distinguished"]},{"year":2022,"claim":"Linking SLFN12 overexpression to reduced CHK1/CHK2 phosphorylation after DNA damage suggested an additional role for SLFN12 in modulating the DNA damage checkpoint, expanding its functional repertoire beyond tRNA cleavage.","evidence":"Lentiviral SLFN12 overexpression in TNBC cells, western blot for pCHK1/pCHK2 after camptothecin, pharmacological CHK1/CHK2 inhibition rescue experiments","pmids":["35430566"],"confidence":"Medium","gaps":["No direct biochemical mechanism connecting SLFN12 RNase to checkpoint kinase regulation was established","Whether the effect on CHK1/CHK2 is a consequence of translational inhibition rather than a specific signaling function was not distinguished","Observations were based on overexpression; endogenous SLFN12 levels were not tested"]},{"year":2024,"claim":"Identification of the GCN2 integrated stress response as a downstream effector of SLFN12-mediated tRNA depletion connected the tRNA cleavage mechanism to a defined stress-sensing pathway that executes cancer cell death.","evidence":"Treatment of patient-derived xenograft GIST models with PDE3A–SLFN12 complex inducer OPB-171775, pathway analysis identifying GCN2 activation","pmids":["38864850"],"confidence":"Medium","gaps":["Whether GCN2 activation is necessary or merely correlative for cell death was not genetically tested","Contribution of other ISR kinases (PERK, HRI, PKR) was not excluded","Whether GCN2 senses the cleaved tRNA fragments or the resulting uncharged tRNA pool was not resolved"]},{"year":null,"claim":"The endogenous physiological function of SLFN12 independent of pharmacological molecular glues remains undefined — it is unknown whether natural ligands or conditions promote PDE3A–SLFN12 complex formation, what kinases and phosphatases regulate the S368/S573 switch, and whether SLFN12 has additional RNA substrates or non-catalytic roles.","evidence":"","pmids":[],"confidence":"Low","gaps":["No endogenous activating signal for PDE3A–SLFN12 complex formation has been identified","Kinase/phosphatase network controlling SLFN12 phosphorylation is uncharacterized","Structural basis for tRNALeu(TAA) selectivity is missing"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,2,3]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,2,5]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[2,3]}],"complexes":["PDE3A-SLFN12 heterotetramer"],"partners":["PDE3A"],"other_free_text":[]},"mechanistic_narrative":"SLFN12 is a cytoplasmic RNase that selectively cleaves tRNALeu(TAA) at its variable loop and acceptor stem, causing ribosome pausing at Leu-TTA codons, global translation inhibition, and apoptosis [PMID:36302897]. Small-molecule \"velcrin\" compounds (DNMDP, anagrelide, nauclefine) act as molecular glues that stabilize a butterfly-shaped PDE3A–SLFN12 heterotetramer; the SLFN12 C-terminal short helix (E552–I558) engages a hydrophobic interface near the PDE3A catalytic pocket, and complex formation increases SLFN12 RNase activity [PMID:34272366, PMID:34707099]. Compound-induced complex assembly also triggers dephosphorylation of SLFN12 at S368 and S573, which is required for full RNase activity and cell death [PMID:35104454]. Downstream, SLFN12-mediated tRNA depletion activates the GCN2 integrated stress response as an effector of cancer cell killing [PMID:38864850]."},"prefetch_data":{"uniprot":{"accession":"Q8IYM2","full_name":"Ribonuclease SLFN12","aliases":["Schlafen family member 12"],"length_aa":578,"mass_kda":67.0,"function":"Ribonuclease which is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling (PubMed:31420216, PubMed:34272366, PubMed:34707099, PubMed:35104454). May play a role in cell differentiation (PubMed:30045019)","subcellular_location":"Nucleus; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/Q8IYM2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLFN12","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLFN12","total_profiled":1310},"omim":[{"mim_id":"614958","title":"SCHLAFEN FAMILY, MEMBER 14; SLFN14","url":"https://www.omim.org/entry/614958"},{"mim_id":"614957","title":"SCHLAFEN FAMILY, MEMBER 13; SLFN13","url":"https://www.omim.org/entry/614957"},{"mim_id":"614956","title":"SCHLAFEN FAMILY, MEMBER 12-LIKE; SLFN12L","url":"https://www.omim.org/entry/614956"},{"mim_id":"614955","title":"SCHLAFEN FAMILY, MEMBER 12; SLFN12","url":"https://www.omim.org/entry/614955"},{"mim_id":"614953","title":"SCHLAFEN FAMILY, MEMBER 11; SLFN11","url":"https://www.omim.org/entry/614953"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SLFN12"},"hgnc":{"alias_symbol":["FLJ10260"],"prev_symbol":[]},"alphafold":{"accession":"Q8IYM2","domains":[{"cath_id":"-","chopping":"5-108","consensus_level":"high","plddt":94.5911,"start":5,"end":108},{"cath_id":"3.30.950","chopping":"128-156_178-319","consensus_level":"high","plddt":91.896,"start":128,"end":319},{"cath_id":"-","chopping":"373-571","consensus_level":"high","plddt":78.5034,"start":373,"end":571}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IYM2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IYM2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IYM2-F1-predicted_aligned_error_v6.png","plddt_mean":82.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLFN12","jax_strain_url":"https://www.jax.org/strain/search?query=SLFN12"},"sequence":{"accession":"Q8IYM2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8IYM2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8IYM2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IYM2"}},"corpus_meta":[{"pmid":"34272366","id":"PMC_34272366","title":"Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34272366","citation_count":70,"is_preprint":false},{"pmid":"34707099","id":"PMC_34707099","title":"Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34707099","citation_count":38,"is_preprint":false},{"pmid":"30379917","id":"PMC_30379917","title":"Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30379917","citation_count":35,"is_preprint":false},{"pmid":"36302897","id":"PMC_36302897","title":"Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death.","date":"2022","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/36302897","citation_count":32,"is_preprint":false},{"pmid":"31749907","id":"PMC_31749907","title":"Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.","date":"2019","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31749907","citation_count":25,"is_preprint":false},{"pmid":"35104454","id":"PMC_35104454","title":"Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death.","date":"2022","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35104454","citation_count":25,"is_preprint":false},{"pmid":"35430566","id":"PMC_35430566","title":"SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy.","date":"2022","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/35430566","citation_count":14,"is_preprint":false},{"pmid":"24689486","id":"PMC_24689486","title":"Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.","date":"2014","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24689486","citation_count":12,"is_preprint":false},{"pmid":"39437010","id":"PMC_39437010","title":"First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/39437010","citation_count":8,"is_preprint":false},{"pmid":"39166256","id":"PMC_39166256","title":"Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression.","date":"2024","source":"Neuro-oncology advances","url":"https://pubmed.ncbi.nlm.nih.gov/39166256","citation_count":6,"is_preprint":false},{"pmid":"38864850","id":"PMC_38864850","title":"A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/38864850","citation_count":6,"is_preprint":false},{"pmid":"35714590","id":"PMC_35714590","title":"A complex puzzle: Regulation of SLFN12 RNase activity by phosphorylation.","date":"2022","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35714590","citation_count":5,"is_preprint":false},{"pmid":"39411532","id":"PMC_39411532","title":"Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12.","date":"2024","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/39411532","citation_count":5,"is_preprint":false},{"pmid":"38832156","id":"PMC_38832156","title":"Overview of Structural and Functional Insights of SLFN12 Associated With Different Diseases.","date":"2024","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/38832156","citation_count":2,"is_preprint":false},{"pmid":"39740094","id":"PMC_39740094","title":"Deciphering the Role of SLFN12: A Novel Biomarker for Predicting Immunotherapy Outcomes in Glioma Patients Through Artificial Intelligence.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39740094","citation_count":2,"is_preprint":false},{"pmid":"39594803","id":"PMC_39594803","title":"SLFN12 Expression Significantly Effects the Response to Chemotherapy Drugs in Triple-Negative Breast Cancer.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39594803","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.10.648087","title":"Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-xL and Bcl-2/Bcl-xL inhibitors","date":"2025-04-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.10.648087","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9031,"output_tokens":1722,"usd":0.026461},"stage2":{"model":"claude-opus-4-6","input_tokens":4958,"output_tokens":2065,"usd":0.114623},"total_usd":0.141084,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"SLFN12 is an RNase enzyme whose activity is required for DNMDP-induced cancer cell death; PDE3A and SLFN12 form a heterotetramer stabilized by DNMDP binding, and interactions between the C-terminal alpha helix of SLFN12 and residues near the PDE3A active site are required for complex formation, which increases SLFN12 RNase activity.\",\n      \"method\": \"Cryo-EM/X-ray structure determination, in vitro RNase assay, mutagenesis of SLFN12 C-terminal helix and PDE3A interface residues, reconstituted complex formation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal/cryo-EM structure plus in vitro enzymatic assay plus mutagenesis, confirmed in multiple independent studies\",\n      \"pmids\": [\"34272366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PDE3A-SLFN12 forms a butterfly-shaped heterotetramer complex stabilized by molecular glue compounds (DNMDP, anagrelide, nauclefine) that bind the PDE3A catalytic pocket and create a new interface recruiting the short helix (E552-I558) of SLFN12 through hydrophobic interactions; the complex blocks protein translation leading to apoptosis.\",\n      \"method\": \"High-resolution cryo-EM structure of PDE3A-SLFN12 complexes isolated from HeLa cells treated with different molecular glues, structure-based analog design validated in cell viability and xenograft assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure with functional validation, independent of PMID:34272366\",\n      \"pmids\": [\"34707099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The physiological substrate of SLFN12 RNase is tRNALeu(TAA); SLFN12 selectively cleaves tRNALeu(TAA) at distinct sequences in its variable loop and acceptor stem, and velcrin-induced PDE3A-SLFN12 complex formation promotes this cleavage in vitro and in cells, leading to ribosome pausing at Leu-TTA codons and global inhibition of protein synthesis, thereby initiating apoptosis.\",\n      \"method\": \"In vitro tRNA cleavage assay with purified SLFN12, mutational analysis of tRNA substrate sequences, ribosome profiling of velcrin-treated cells, measurement of tRNALeu(TAA) levels and global protein synthesis in sensitive cancer cells\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted RNase assay with substrate mutagenesis plus cellular ribosome profiling, multiple orthogonal methods\",\n      \"pmids\": [\"36302897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Molecular glue compounds induce PDE3A-SLFN12 complex formation, which increases SLFN12 protein stability in the cytoplasm and induces dephosphorylation of SLFN12 at serines 368 and 573; this dephosphorylation is required for cell death and promotes SLFN12 rRNA RNase activity.\",\n      \"method\": \"Mutational analysis of phosphoserine residues, western blot for phosphorylation status, cell viability assays with phosphomimetic/phospho-null mutants, in vitro RNase assay with dephosphorylated vs. phosphorylated SLFN12\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis of specific phosphosites with in vitro RNase activity readout and cell death phenotype\",\n      \"pmids\": [\"35104454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SLFN12 overexpression in triple-negative breast cancer cells reduces CHK1 and CHK2 phosphorylation after DNA damage (camptothecin treatment), and CHK1/CHK2 inhibition diminishes the sensitization to carboplatin conferred by SLFN12 overexpression, placing SLFN12 upstream of checkpoint kinase signaling in DNA damage response.\",\n      \"method\": \"Lentiviral SLFN12 overexpression, western blot for pCHK1/pCHK2, pharmacological CHK1/CHK2 inhibition (AZD7762), crystal violet viability assay in multiple TNBC cell lines\",\n      \"journal\": \"Cancer genomics & proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic epistasis with pharmacological inhibitor rescue, replicated in multiple cell lines but no direct biochemical mechanism established\",\n      \"pmids\": [\"35430566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SLFN12 RNase-mediated cell death in GISTs activates the GCN2 (general control non-derepressible 2) kinase and its downstream integrated stress response as an effector pathway mediating anticancer activity.\",\n      \"method\": \"OPB-171775 (PDE3A-SLFN12 complex inducer) treatment in patient-derived xenograft GIST models, mechanistic pathway analysis identifying GCN2 activation as downstream effector\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway placement in PDX models, consistent with known tRNA cleavage mechanism activating GCN2, but limited biochemical detail reported\",\n      \"pmids\": [\"38864850\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLFN12 is a cytoplasmic RNase that, when recruited into a heterotetramer with PDE3A by molecular glue compounds (velcrins), undergoes dephosphorylation at S368/S573 and increased enzymatic activity, selectively cleaving tRNALeu(TAA) to cause ribosome pausing at Leu-TTA codons, global translation inhibition, and apoptotic cell death; complex formation requires the C-terminal alpha helix of SLFN12 engaging a compound-modified hydrophobic interface near the PDE3A catalytic site.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SLFN12 is a cytoplasmic RNase that selectively cleaves tRNALeu(TAA) at its variable loop and acceptor stem, causing ribosome pausing at Leu-TTA codons, global translation inhibition, and apoptosis [PMID:36302897]. Small-molecule \\\"velcrin\\\" compounds (DNMDP, anagrelide, nauclefine) act as molecular glues that stabilize a butterfly-shaped PDE3A–SLFN12 heterotetramer; the SLFN12 C-terminal short helix (E552–I558) engages a hydrophobic interface near the PDE3A catalytic pocket, and complex formation increases SLFN12 RNase activity [PMID:34272366, PMID:34707099]. Compound-induced complex assembly also triggers dephosphorylation of SLFN12 at S368 and S573, which is required for full RNase activity and cell death [PMID:35104454]. Downstream, SLFN12-mediated tRNA depletion activates the GCN2 integrated stress response as an effector of cancer cell killing [PMID:38864850].\",\n  \"teleology\": [\n    {\n      \"year\": 2021,\n      \"claim\": \"Establishing that SLFN12 possesses RNase activity and forms a structurally defined heterotetramer with PDE3A resolved a key question about how velcrin compounds kill cancer cells — not through PDE3A catalytic inhibition but through induced proximity that activates SLFN12 enzymatic function.\",\n      \"evidence\": \"Cryo-EM and X-ray crystallography of PDE3A–SLFN12 complexes, in vitro RNase assays, and mutagenesis of the SLFN12 C-terminal helix and PDE3A interface residues\",\n      \"pmids\": [\"34272366\", \"34707099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Physiological RNA substrate of SLFN12 RNase was not identified\",\n        \"Mechanism by which RNase activity leads to cell death was unclear\",\n        \"Whether endogenous (non-drug-induced) signals regulate complex formation was unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of tRNALeu(TAA) as the selective physiological substrate of SLFN12 explained how its RNase activity causes translation arrest and apoptosis — cleavage depletes a specific tRNA, stalling ribosomes at cognate codons genome-wide.\",\n      \"evidence\": \"In vitro tRNA cleavage assays with purified SLFN12, substrate mutagenesis defining cleavage sites, and ribosome profiling showing pausing at Leu-TTA codons in velcrin-treated cells\",\n      \"pmids\": [\"36302897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether SLFN12 cleaves additional tRNA species under different conditions was not resolved\",\n        \"Structural basis for tRNALeu(TAA) selectivity over other tRNAs was not determined\",\n        \"How ribosome pausing at specific codons triggers apoptotic commitment remained undefined\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that velcrin-induced complex formation triggers dephosphorylation of SLFN12 at S368 and S573, and that this dephosphorylation is required for RNase activation and cell death, revealed a post-translational regulatory switch controlling SLFN12 enzymatic output.\",\n      \"evidence\": \"Phosphomimetic and phospho-null mutagenesis, western blot for phosphorylation status, in vitro RNase assay comparing phosphorylated and dephosphorylated SLFN12, and cell viability assays\",\n      \"pmids\": [\"35104454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the phosphatase(s) responsible for S368/S573 dephosphorylation was not established\",\n        \"The kinase(s) maintaining basal SLFN12 phosphorylation were not identified\",\n        \"Whether dephosphorylation alters SLFN12 substrate specificity or only catalytic rate was not distinguished\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking SLFN12 overexpression to reduced CHK1/CHK2 phosphorylation after DNA damage suggested an additional role for SLFN12 in modulating the DNA damage checkpoint, expanding its functional repertoire beyond tRNA cleavage.\",\n      \"evidence\": \"Lentiviral SLFN12 overexpression in TNBC cells, western blot for pCHK1/pCHK2 after camptothecin, pharmacological CHK1/CHK2 inhibition rescue experiments\",\n      \"pmids\": [\"35430566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct biochemical mechanism connecting SLFN12 RNase to checkpoint kinase regulation was established\",\n        \"Whether the effect on CHK1/CHK2 is a consequence of translational inhibition rather than a specific signaling function was not distinguished\",\n        \"Observations were based on overexpression; endogenous SLFN12 levels were not tested\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of the GCN2 integrated stress response as a downstream effector of SLFN12-mediated tRNA depletion connected the tRNA cleavage mechanism to a defined stress-sensing pathway that executes cancer cell death.\",\n      \"evidence\": \"Treatment of patient-derived xenograft GIST models with PDE3A–SLFN12 complex inducer OPB-171775, pathway analysis identifying GCN2 activation\",\n      \"pmids\": [\"38864850\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether GCN2 activation is necessary or merely correlative for cell death was not genetically tested\",\n        \"Contribution of other ISR kinases (PERK, HRI, PKR) was not excluded\",\n        \"Whether GCN2 senses the cleaved tRNA fragments or the resulting uncharged tRNA pool was not resolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous physiological function of SLFN12 independent of pharmacological molecular glues remains undefined — it is unknown whether natural ligands or conditions promote PDE3A–SLFN12 complex formation, what kinases and phosphatases regulate the S368/S573 switch, and whether SLFN12 has additional RNA substrates or non-catalytic roles.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No endogenous activating signal for PDE3A–SLFN12 complex formation has been identified\",\n        \"Kinase/phosphatase network controlling SLFN12 phosphorylation is uncharacterized\",\n        \"Structural basis for tRNALeu(TAA) selectivity is missing\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005357801\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [\n      \"PDE3A-SLFN12 heterotetramer\"\n    ],\n    \"partners\": [\n      \"PDE3A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}